Kevin Tang
SKIPTang Capital Management
MD/MBA biotech activist with genuine scientific edge in micro-cap pharma, but the speculative, small-cap, activist-driven approach is incompatible with our passive, downside-first philosophy.
Healthcare & Biotech Specialists
Score Breakdown
Investment Philosophy & Portfolio Style
Philosophy
Tang is a deep-value activist investor in the healthcare/biotech space. His MD background allows him to independently evaluate drug pipelines, clinical data, and the scientific merits of biotech companies. His approach combines scientific due diligence with activist value investing — he looks for undervalued biotech/pharma companies where he can influence outcomes through board representation, strategic initiatives, or operational improvements. He is willing to engage in proxy fights and hostile takeover attempts when he believes value is being destroyed by incumbent management. The philosophy is value-oriented but with an activist catalyst — he does not just buy and hold, he actively works to create value. He has also been involved in acquiring companies and taking them private.
Portfolio Style
Concentrated portfolio of 10-20 positions, almost exclusively in small and micro-cap biotech, specialty pharma, and medical device companies. Many positions are 5-15% ownership stakes where Tang seeks board representation. The portfolio is high-risk/high-reward — small biotech companies can be highly volatile and some can go to zero. Tang often takes control positions or near-control positions. The activist approach means he is not a passive investor — he is deeply involved in the governance and strategy of his portfolio companies. Turnover varies — some positions are held for years through activist campaigns, while others are more tactical.
Background
Kevin Tang founded Tang Capital Management in 2002. He holds both an MD and an MBA, giving him a rare combination of medical/scientific expertise and business/financial acumen. Before founding Tang Capital, he worked in healthcare investment banking and biotechnology equity research. Tang Capital is a San Diego-based investment firm focused exclusively on life sciences and healthcare, managing estimated assets of $500 million to $1 billion. Tang is known as an activist investor in small and micro-cap biotech and pharma companies, frequently taking board seats, pushing for strategic changes, and sometimes acquiring companies outright. He has been involved in numerous proxy fights and activist campaigns in the biotech space. Notable involvement includes MiMedx Group (where he pushed for governance reforms after an accounting scandal) and various small-cap pharma companies where he sought to unlock value through M&A or operational changes.
Track Record
Tang Capital's track record is difficult to assess precisely because the firm is private and does not publicize returns. Individual activist campaigns have had mixed results. The MiMedx involvement was notable — Tang pushed for governance reforms after accounting irregularities, and the company eventually recovered. However, small-cap biotech activism is inherently high-risk, and some campaigns have resulted in losses. The firm has survived and operated for 20+ years, which suggests at least reasonable overall performance. Tang's MD/MBA combination gives him a genuine analytical edge in the space, but the micro-cap biotech focus means the portfolio carries substantial risk of individual positions going to zero due to clinical trial failures or funding gaps.
Notable Holdings
Notable current and historical positions include: MiMedx Group (activist campaign for governance reform), Rigel Pharmaceuticals, Retrophin (now Arcus Biosciences), various small-cap specialty pharma and biotech companies. The specific portfolio changes frequently as activist campaigns resolve and new opportunities arise. Tang has also been involved in taking companies private or facilitating M&A transactions.
Transparency & Integrity
Transparency(Score: 3/10)
Low. Tang Capital is a private fund with limited public disclosure. The firm files 13F reports showing public equity holdings, but the activist nature of the strategy means much of the value creation happens through private negotiations, board discussions, and strategic initiatives that are not publicly visible until proxy filings or press releases. Tang's personal public profile is relatively low — he does not give frequent interviews or speak at major investment conferences. The firm's website provides minimal information.
Integrity(Score: 7/10)
Generally positive. Tang's activist campaigns have often been aimed at improving corporate governance — his involvement with MiMedx was specifically about holding management accountable for accounting irregularities, which is a pro-shareholder stance. His MD background provides genuine scientific credibility rather than financial engineering. No major SEC enforcement actions or fraud allegations. However, activist investing in micro-cap biotech can create conflicts of interest, and the adversarial nature of proxy fights can sometimes blur the line between value creation and value extraction. On balance, Tang appears to be a genuine value-oriented activist with real domain expertise.
Relevance to Us
Low alignment. While Tang's concentrated, value-oriented approach and genuine scientific expertise are admirable, his focus on micro-cap biotech activism is fundamentally incompatible with our investment approach. The micro-cap biotech space is where our 'cannot compute floor price' category applies most directly — these companies often have no revenue, no tangible assets, and binary clinical trial outcomes that can send them to zero. Tang's activist approach requires deep involvement in corporate governance and strategy, which we cannot replicate. The position sizes in micro-cap names are too small for most of Tang's ideas to be relevant to a broader portfolio. His edge comes from activism and board-level influence, not from passive ownership — and we are passive investors.